The TROPION-Breast01 phase III study shows that while the ADC datopotamab deruxtecan (Dato-DXd) improves progression-free survival, it does …
The TROPION-Breast01 phase III study shows that while the ADC datopotamab deruxtecan (Dato-DXd) improves progression-free survival, it does …
Grace Therapeutics reports that its Phase III STRIVE-ON trial showed GTx-104 significantly reduces clinically significant hypotension and improves …
New clinical-stage anti-obesity therapies began breaking ground—designed not just to shed pounds, but to retain muscle, offering a …
Parexel reveals strategic plans to ramp up its Indian operations—underscoring India’s emerging prominence as a critical node in …
Johnson & Johnson discontinues three neuroscience programs—including the sleep-focused seltorexant—realigning its R&D priorities and signaling a strategic course …
Vertex Pharmaceuticals earns approval for JOURNAVX™ (suzetrigine), a ground-breaking oral NaV1.8 pain channel inhibitor designed to target moderate-to-severe …
Allakos faced a major setback as its chronic hives drug AK006 failed to outperform placebo in a key …
A new survey finds that over 80% of healthcare professionals notice sex-related differences in disease progression and treatment …
At the 2025 ASCO Gastrointestinal Cancers Symposium, ALX Oncology presents promising Phase II data showing that evorpacept, a …
Oncolytics Biotech discloses compelling new pelareorep combination data—in anal and pancreatic cancer cohorts—highlighting durable responses and tolerable safety …
Already a subscriber? Log in